NFL Biosciences Is Strengthening Its Personalized Medicine Approach to Smoking Cessation With a New Patent Application
NFL Biosciences Is Strengthening Its Personalized Medicine Approach to Smoking Cessation With a New Patent Application
Personalized medicine approach that could represent a first in smoking cessation
Biomarker rooted in NFL-101’s immunomodulatory mechanism of action
Rigorous analytical validation paving the way for an accessible laboratory test
Strategy aimed at improving clinical efficacy, reducing the size of Phase 3 trials and strengthening the program’s partnership attractiveness
NeuroScientific hails 80% clinical response in Crohn’s stem cell program
US Agency Broadens Coverage Of Personalis Breast Cancer Test - Personalis (NASDAQ:PSNL)
How Timely, Precise Lab Data Drive Decisions from Discovery to Post-Marketing Surveillance
In Alzheimer’s, Bristol Myers sees big promise beyond amyloid
Immunovant shares surge on arthritis trial data
Pharmalittle: We're reading about a Parkinson's drug setback, a Merck lung cancer therapy, and more
As calls for COINS Act expansion grow, will new rules sweep up China biotech licensing?
With Voxzogo under pressure, BioMarin touts trial win in label expansion bid
Personalis to Highlight Breadth of NeXT Personal® Ultra-Sensitive ctDNA Data at ASCO 2026 Annual Meeting, Including Podium…
Mercy BioAnalytics to Present Data at ASCO Evaluating Clinical Performance of a Blood-Based Lung Cancer Early Detection Assay in…
The FDA's new path, the status of animal testing, and other biotech news from The Readout
NeuroScientific Biopharmaceuticals has reported an 80% response rate from five Crohn’s disease patients treated with its…
ImmunityBio shares rise after the FDA accepted ANKTIVA's sBLA for NMIBC, with Phase 2/3 data showing durable bladder cancer…
Cytokinetics executives said their first FDA-approved drug is off to a strong start as it goes up against its Bristol Myers…
